Nike recorded a lower profit and said it expects revenue to a decline in its current quarter. The stock fell 11% to $58.62 in after-hours trading Thursday. Cassava Sciences said the FDA had placed a ...
Cassava Sciences has pivoted from failed Alzheimer’s trials to developing simufilam for TSC-related epilepsy, but has yet to start human trials. A 46.98% share price surge followed CEO Richard Barry’s ...
Fintel reports that on October 6, 2025, LUCID CAPITAL MARKETS initiated coverage of Cassava Sciences (NasdaqCM:SAVA) with a Buy recommendation. As of September 30, 2025, the average one-year price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results